These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8251698)

  • 1. Meaningful interpretation of risk reduction from clinical drug trials.
    McCormack JP; Levine M
    Ann Pharmacother; 1993 Oct; 27(10):1272-7. PubMed ID: 8251698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [How I explore ... a risk difference in the occurrence of an event in clinical trials].
    Scheen AJ; Ernest P; Jandrain B
    Rev Med Liege; 2012 Nov; 67(11):597-602. PubMed ID: 23346831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data.
    Lonn EM; Yusuf S
    Can J Cardiol; 1997 Oct; 13(10):957-65. PubMed ID: 9374952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal.
    Zanchetti A; Thomopoulos C; Parati G
    Circ Res; 2015 Mar; 116(6):1058-73. PubMed ID: 25767290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.
    Brozek JL; Guyatt GH; Schünemann HJ
    Health Qual Life Outcomes; 2006 Sep; 4():69. PubMed ID: 17005037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative approaches to investigator-initiated, multicentre paediatric clinical trials in Canada.
    Kelly LE; Richer L; Ali S; Plint AC; Poonai N; Freedman SB; Knisley L; Shimmin C; Hickes S; 't Jong GW; Pechlivanoglou P; Offringa M; Lacaze T; Klassen TP
    BMJ Open; 2019 Jun; 9(6):e029024. PubMed ID: 31253625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative risk, absolute risk and number needed to treat: basic concepts.
    Carneiro AV
    Rev Port Cardiol; 2009 Jan; 28(1):83-7. PubMed ID: 19388495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The case for practical clinical trials in psychiatry.
    March JS; Silva SG; Compton S; Shapiro M; Califf R; Krishnan R
    Am J Psychiatry; 2005 May; 162(5):836-46. PubMed ID: 15863782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What can we learn from clinical trials of anticonvulsant drugs in epilepsy?
    Perucca E
    Eur J Pain; 2002; 6 Suppl A():35-44. PubMed ID: 11888239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
    Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
    JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical appraisal of trials for validation of 'risk-guided' cardiovascular disease prevention therapy.
    Castro A; Rosillo SO; Alonso A; Pedersen T
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):33-6. PubMed ID: 22801068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good enough: a primer on the analysis and interpretation of noninferiority trials.
    Kaul S; Diamond GA
    Ann Intern Med; 2006 Jul; 145(1):62-9. PubMed ID: 16818930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Communicating benefit and risk.
    Baglin T
    Br J Haematol; 2009 Jun; 146(1):31-3. PubMed ID: 19438473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy.
    Rothwell PM; Mehta Z; Howard SC; Gutnikov SA; Warlow CP
    Lancet; 2005 Jan 15-21; 365(9455):256-65. PubMed ID: 15652609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The necessity of placebo application in psychotropic drug trials.
    Benkert O; Maier W
    Pharmacopsychiatry; 1990 Sep; 23(5):203-5. PubMed ID: 2251299
    [No Abstract]   [Full Text] [Related]  

  • 20. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.